Navigation Links
Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
Date:4/5/2011

ry movements was shown across multiple assessment points. After the seven-day washout period most patients' AIMS scores returned to their baseline levels. The adverse events reported during administration of study drug were transient and mild or moderate including one subject with dizziness and one with restlessness. One subject became anxious and agitated seven days after stopping the study medication due to return of baseline-intensity dyskinesia.

About the Abnormal Involuntary Movement Scale (AIMS)

The AIMS was developed in 1976, and has been used extensively in movement disorder assessments. It consists of ten distinct ratings that are observed both spontaneously and upon activation. Ratings one through seven score facial, extremity and trunk movements; items eight through ten are overall global judgments of severity, incapacitation and patient awareness. All ten ratings are scored on a zero to four scale with zero being rated as none, and four being rated as severe.

About NBI-98854

VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) among nerve cells. NBI-98854, developed in the Neurocrine laboratories, is a novel, highly-selective VMAT2 inhibitor that modulates dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines thereby reducing the likelihood of "off target" side effects. NBI-98854 is designed to provide low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive dopamine depletion.

NBI-98854 may well be useful in other disorders such as Huntington's chorea, schizophrenia, Tourette's syndrome, and Tardive Dystonia.

Next Steps for NBI-98854

All of the clinical work to date for NBI-98854 has been conducted in Canada. The Company plans to open an IND
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
2. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
3. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
4. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
5. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
6. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
8. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
9. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
10. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
11. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... N.Y. , March 4, 2015  Brooklyn residents ... their acute and chronic pain and injuries. Nunzio ... announce the grand opening of his NJS Physical Medicine ... on Thursday, March 5, 2015. Health Plus ... facility, which is located at 1178 Flatbush Avenue. This ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biologics and Biosimilars Industry Report ... The Global Biologics and Biosimilars Industry ... on the current state of the biologics and ... basic overview of the industry including definitions, classifications, ...
(Date:3/4/2015)... Proove Biosciences , a ... excited to announce the launch of their CME-accredited ... Management of Pain”. , The continuing medical education ... next year. The focus of the program is ... pain treatments, integrate appropriate pain management techniques, and ...
(Date:3/4/2015)... Korea , March 4, 2015 Vegalab ... company, in August of last year. As part of ... Kyung Bon Koo continuing his role as CEO ... President of Vegalab S.A., will work alongside Koo and ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 Koo ...
Breaking Biology Technology:NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Global Biologics and Biosimilars Industry Report 2015-2020 2Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3
... Sept. 24 Pressure,BioSciences, Inc. (Nasdaq: PBIO ... activities, including the expansion of its domestic sales,force, ... Frankfurt Stock Exchange, and,reaffirmation of guidance relative to ... 1) Domestic Sales Force: the Company has hired ...
... Inc., a leading developer of advanced medical devices ... J. Daniel,Cole as the company,s new Chairman of ... partner with Spray Venture Partners, a venture,capital firm ... brings twenty years of medical device operational experience,having ...
... Results for Memory and Cognition Validate Clinical ... ... Corporation plc,(NASDAQ: AMRN ) ("Amarin" or "Company") announced that ... ultra-pure,eicosapentanoic acid (EPA) have been published in the "Journal of,Neurochemistry" ...
Cached Biology Technology:Pressure BioSciences, Inc. Provides Corporate Update 2Pressure BioSciences, Inc. Provides Corporate Update 3OmniSonics Appoints J. Daniel Cole Chairman of the Board 2Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 2Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 3Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 4Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 5
(Date:3/2/2015)... , March 2, 2015  Businesses have a ... protection company Tharon Rankins Enterprises has announced the ... an ultra-safe way for businesses to protect their ... transactions. Beconux is a biometric ... Enterprises. Functioning similarly to an ATM machine, the ...
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ... through 2020. Also, a seven-year historic analysis is provided for these ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Cepheid to Webcast Upcoming Financial Presentations 2
... MADISON, WI, SEPTEMBER 28, 2009 -- Emphasizing ... as mass-volume relationships, can help undergraduates learn real-world, ... in soil science careers. Drs. Josh Heitman ... Science Department, highlighted this need for quantitative measurement ...
... of Pittsburgh received two grants totaling more than $5 ... explore new methods for cultivating replacement cells from existing ... R01 (T-R01) grant presented to Eric Lagasse, a professor ... researcher in Pitt and UPMC,s jointly operated McGowan Institute ...
... University of California, San Diego (UC San Diego), The ... Research Foundation (GNF) and other institutions have constructed a ... central metabolic network of the bacterium Thermotoga maritima ... time scientists have developed such a comprehensive model of ...
Cached Biology News:Help students think like soil scientists 2Help students think like soil scientists 3Pitt researchers net $5 million from NIH to explore better ways to grow cells for regenerative medicine 2Pitt researchers net $5 million from NIH to explore better ways to grow cells for regenerative medicine 3Comprehensive understanding of bacteria could lead to new insights into many organisms 2
... We deliversoluble protein or No Charge to ... best soluble protein results , 24 solubility ... , Powerful results on your most insoluble ... Service (SOS) uses proprietary tools and know-how ...
... scale kinase profiling, quantitative measurement of ... research built on the flexible and ... These microarrays are available as part ... - Peptide Microarray Service. ...
... Microarrays designed for immunological studies, ... on the flexible and powerful Paraflo ... are available as part of our ... Custom Probe Content Probe ...
... Molecular Imaging (MI) Software for use in ... and drug discovery applications. The Regulatory Edition ... Drug Administrations Code of Federal Regulations Title ... [21 CFR Part 11]. KODAK MI Software, ...
Biology Products: